Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly?
Shares of Viking Therapeutics took off recently after the company released some promising data about its GLP-1 drug.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.